Vaxart Inc.
South San Francisco, CA
Vaxart is a clinical-stage public company trading on NASDAQ under the symbol VXRT aimed at developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies have been completed; seasonal influenza, for which a Phase 2 challenge study was recently completed; and respiratory syncytial virus, or RSV, a common cause of respiratory tract infections. In addition, Vaxart has two programs targeting human papillomavirus, or HPV. The Company is developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18, and is also in Phase 2 with BTA074, an antiviral treatment for condyloma caused by HPV types 6 and 11. The company was founded in 2004 and has offices and laboratories in South San Francisco, CA.